<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00903981</url>
  </required_header>
  <id_info>
    <org_study_id>CWP-AVA-301</org_study_id>
    <nct_id>NCT00903981</nct_id>
  </id_info>
  <brief_title>Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil</brief_title>
  <acronym>ALERT</acronym>
  <official_title>A Randomized, Placebo Controlled, Double Blind, Multicenter Therapeutic Confirmatory Clinical Study for the Evaluation of the Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the efficacy and the safety of Avanafil 100mg, 200mg
      or placebo administered orally for 12 weeks in patients with erectile dysfunction. The
      efficacy is evaluated by IIEF, SEP Q2 and Q3 and GEAQ and the safety is evaluated by
      laboratory tests, vital signs, physical examination and adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of EF domain score in the IIEF(The International Index of Erectile Function)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of successful rate in SEPQ2,Q3,Q4,Q5 Change of score in other domains of IIEF Change of IIEF Q3 and Q4 score GEAQ The rate of normal erectile function</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Avanafil 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Avanafil 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avanafil</intervention_name>
    <description>2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse</description>
    <arm_group_label>Avanafil 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avanafil</intervention_name>
    <description>2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse</description>
    <arm_group_label>Avanafil 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male subjects aged 19 to 70 with history of erectile dysfunction for at least 6 months

          -  subjects have stable monogamous relationships

          -  their partners are free from pregnancy and lactation and well prevent conception

          -  subjects consented to participate in the clinical study in writing

          -  subjects attempted sexual intercourse at least 4 times in separate days during 4
             weeks' free run-in period, and failure rate is over 50%

        Exclusion Criteria:

          -  history of spinal cord injury or radical prostatectomy

          -  subjects whose penises are anatomically deformed

          -  erectile dysfunction due to neurogenic or endocrine cause

          -  subjects who have uncontrolled major psychiatric disorder and do not accept therapies
             or have significant neurological abnormalities

          -  history of cancer chemotherapy within 1 year

          -  subjects who are addicted to alcohol or have continuously misused dependent drugs

          -  subjects who have hepatic dysfunction(GOP,GPT â‰¥ 3xUNL) or renal dysfunctions(serum
             creatinine &gt; 2.0)

          -  subjects who have uncontrollable diabetes(FPG&gt;180)

          -  subjects sho have proliferative diabetic retinopathy

          -  history of stroke, transient ischemic attacks, myocardial infarction, heart failure
             that needs to be medically treated, unstable angina or fatal arrhythmia or coronary
             artery bypass graft within 6 months

          -  serious hypotension or uncontrollable severe hypertension

          -  hematological disorders that is likely to be developed into priapism such as sickle
             cell disease, multiple myeloma, leukemia

          -  subjects who have retinitis pigmentosa

          -  subjects who suffered from serious GI bleeding disorder within 1 year

          -  subjects who took other PDE5 inhibitors or ED therapies within 2 weeks

          -  subjects who use non-concomitant medications(Nitrate/NO donors, Androgens,
             anti-androgen, trazodone, Anticoagulant,over-the-counter drugs known to inhibit the
             activity of CYP3A4)

          -  history of hypersensitivity to the PDE5 inhibitors or not responded to them

          -  subjects who have hypoactive sexual desire

          -  subjects who have no intention of having sexual intercourses 4 times in separate days
             during 4 weeks' free run-in period

          -  subjects who took other investigational products within 30 days before this clinical
             study

          -  subjects who are judged to be unsuitable to the clinical study by other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Kwan Park, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Se Woong Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic Seoul medical center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Suk Hyun, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeongsang National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Je Jong Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nam Cheol Park, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung Won Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Seung Paick, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae young Ahn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki Hak Moon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeungnam University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo Sik Chung, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha womans university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kweon Sik Min, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje university Pusan paick hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Kyu Suh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kwang Sung Park, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dae Yul Yang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangdong Sacred Heart Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk national university hospital</name>
      <address>
        <city>Chonju</city>
        <state>Cholabukdo</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2009</study_first_submitted>
  <study_first_submitted_qc>May 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2009</study_first_posted>
  <last_update_submitted>April 22, 2010</last_update_submitted>
  <last_update_submitted_qc>April 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>ChoongWae Pharma Corporation(Hyun Yoon Jeong)</name_title>
    <organization>ChoongWae Pharma Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

